Extracellular vesicles (EVs) mediate the intercellular transfer of RNAs, which alter gene expression in target cells. EV heterogeneity has limited progress towards defining their physiological functions and utility as disease-specific biomarkers. CD63 and MHC1 are widely used as markers to purify EVs. CD47 is also present on EVs and alters their effects on target cells, suggesting that specific surface markers define functionally distinct EVs. This hypothesis was addressed by comparing Jurkat T cell EVs captured using CD47, CD63, and MHC1 antibodies. These EV subsets have similar sizes but divergent RNA contents. Apart from differences in numbers of nonannotated transcripts, CD63 + , MHC1 + , and CD47 + EVs have similar overall contents of most noncoding RNA classes, but the relative enrichment of specific RNAs differs. The enrichment of micro-RNAs is highly divergent, and some including miR320a are selectively concentrated in CD47 + EVs. Small nucleolar RNAs including SNORD116@ and SNHG10 are also selectively enriched in CD47 + EVs, whereas no small nuclear RNAs are enriched in CD47 + EVs.
Ongoing investigations of extracellular vesicles (EVs) are revealing diverse and complex functions in cell-cell communication, mediated in part by their role in the intercellular transfer of RNAs [1] [2] [3] . The presence of disease-associated EVs in biological fluids such as saliva, urine, cerebrospinal fluid, and blood 4, 5 is providing a new source for biomarkers for diseases including cancer 6 , osteo-and rheumatoid arthritis 7 , and neurodegenerative disorders 8 . Engineered EVs are also promising deliver vehicles for therapeutic uses including the targeted delivery of miRNAs 9, 10 . To achieve these goals, barriers must be overcome to standardize EV nomenclature 11 , characterize their heterogeneity 12 , and define the molecular mechanisms controlling passive or active sorting of specific RNAs into different types of EVs 13 . To investigate the mechanisms of EV biogenesis and RNA sorting from their parent cells it is also important to consider biases introduced by specific methods for isolation and processing of EVs 14, 15 . To date no standard method has been established for isolation of EVs. Various surface markers of EVs have been identified. Antibodies to CD9, CD63, CD81, and MHC class 1 (MHC1) have been used for immunoaffinity purification of EVs bearing these membrane proteins [16] [17] [18] , but the efficiency of these capture methods is not well documented and requires optimization of the ratio of magnetic particles versus EVs. Furthermore, it is unclear whether EVs produced by the same cell but lacking these markers differ in their RNA content or functional activity.
CD47 is present on a subset of CD63
+ and MHC1 + EVs. Bulk EVs isolated from Jurkat T cell conditioned medium using a commercial polymeric precipitation method were fractionated using ~15 nm magnetic nanoparticles (MNPs) conjugated with antibodies specific for the exosome markers CD63, MHC1, and CD47. Efficiency of the capture using the CD63 antibody MNPs was estimated to be 83% for Jurkat T cell EVs and 88% for CD47-deficient JinB8 EVs based on recapture followed by flow analysis of Bodipy FL-labeled EVs from the two cell lines (Fig. S1 ). Flow cytometry analysis using fluorescence thresholding with a PE-conjugated CD47 antibody was used to examine CD47 expression on the CD63 + and MHC1 + EV populations released by Jurkat cells (Fig. 1c) . This analysis showed that 20.5% and 17.6%, respectively, of CD63 + and MHC1 + EVs are positive for CD47 (Fig. 1c) .
Analysis of CD63
+ and MHC1 + EVs isolated from CD47-deficient JinB8 cells confirmed the specificity of detecting CD47 antibody binding to EVs (Fig. 1d) .
Flow cytometry analysis using fluorescence thresholding was calibrated using 160-500 nm MegaMix-SSC fluorescent calibration beads to characterize the size distribution of CD63
+ and MHC1 + EVs that express CD47 (Figs S2 and S3, Fig. 1e ). Both subsets of CD47 + EVs are predominantly 160-240 nm in size, but larger CD47 + /MHC1 + EVs (black bars) were more prevalent than CD47 + /CD63 + EVs (red bars). Flow analysis of CD63 staining of EVs capture using anti-CD47 MNPs confirmed the presence of EVs bearing both surface proteins (Fig. 1f) . , and CD47 + EVs and from the respective uncaptured fractions of CD63 − , MHC1 − , and CD47 − EVs using a Qiagen miRNeasy micro kit that preserves all classes of RNAs. The RNA quality was accessed by Bioanalyzer (Fig. S4) . Libraries enriched in smaller RNAs were prepared using the Clontech SMARTer small RNA-seq kit for the Illumina NextSeq. 500 platform combined with bead-based size selection. Sequencing was done with 12.5 million reads per sample with 75 bp reads, multiplexing 32 samples on a 400 million read flow cell.
RNA Sequencing Work Flow. Because transfer of RNAs is a major mediator of EV
The small RNA sequencing data was analyzed using DNASTAR with three methods. For total RNA evaluation, the standard RNA sequencing work flow was used ( Fig. S5 Method I ). RNA sequencing reads were aligned using the DNASTAR ArrayStar workflow to either small coding/noncoding RNAs (CDS, rRNA, tRNA, ncRNA, tmRNA and miscRNA) or to miRNA (hairpin.fa and mature.fa) reference databases. To further evaluate small RNAs, we used miRNA sequencing DNASTAR -ArrayStar work flow, which evaluates long noncoding RNAs and other small RNAs (Fig. S5 Method II) . To further evaluate miRNA, we used a SeqMan NGen assembly aligned with miRbase, and analysis was performed using the RNA-Seq analysis workflow of ArrayStar (Fig. S5 Method  III) . A full description of the work flows is in the Methods section.
CD63
+ , CD47 + and MHC1 + EVs differentially enrich noncoding RNAs. Alignment of the RNA sequencing data using method (I) to align coding and non-coding RNAs to a reference genome revealed that all uncaptured EV fractions following depletion of EVs expressing each of the three markers have similar noncoding RNA compositions (Fig. 2d-f and Table A) . EVs captured using anti-CD63 showed the greatest enrichment of other classes of noncoding RNAs relative to nonannotated RNAs (locRNA, Fig. 2b ). EVs captured using anti-CD47 showed intermediate enrichment, whereas EVs captured using anti-MHC1 showed only modest depletion of locRNAs relative to the uncaptured controls (Fig. 2a,c 
, MHC1
+ and CD47 + EVs with uncaptured EVs lacking each respective marker and selected transcripts with at least 2-fold higher expression in captured versus uncaptured EVs and a minimum log 2 total RPM = 2 ( Fig. 3a-c) (Fig. 3b) . Captured versus uncaptured MHC1
+ EVs showed 799 ≥ 2-fold differentially expressed transcripts (Fig. 3c) . We next determined the number of transcripts in specific classes of RNAs that were significantly enriched in the three subsets of EVs. Similar numbers of lncRNAs and locRNAs were enriched by the three antibodies, whereas CD47 + EVs showed a notable absence of snRNA enrichment but enrichment of more snoRNAs (Fig. 3d-g ). In contrast, MHC1
+ EVs showed enrichment of more tRNAs than either CD63 + or CD47 + EVs (Fig. 3d) . Fig. 3a) . Among them, 205 with ≥ 8-fold enrichment (Fig. 3a) and 65 of those genes were statistically significant at p < 0.05, including long noncoding and nonannotated RNAs, tRNA, and ribosomal protein RNAs. CD63 + EVs were enriched in 271 transcripts, which included small nucleolar RNAs, lncRNAs, ribosomal protein RNAs, small nuclear RNAs and tRNAs (Fig. 5a -e and Supplemental Table 2 , Fig. 3b ). Among them, enrichment for 36 genes was statistically significant at p < 0.05. They included SnoRNAs, nonannotated RNAs, ribosomal protein RNAs, and a minor population of long noncoding RNAs. MHC1 + EVs were enriched in 265 transcripts, which included tRNAs, lncRNA, ribosomal protein RNA, small nuclear and nucleolar RNAs (Fig. 6a -e and Supplemental Table 3 , Fig. 3c ). MHC1
+ EVs contained the largest number of enriched tRNAs, but had the least number of enriched lncRNAs, ribosomal protein RNAs, and small nucleolar RNAs. Of these only 4 were significant at p < 0.05. Further comparison of transcript levels between CD47 + and CD63 + EVs, identified 628 (≥2-fold) differentially expressed RNAs (Fig. S6a) , and 25 of these were significant at p < 0.05 (Fig. S6b) , while 689 (≥2-fold) were differential enriched between CD47 + and MHC1 + EVs (Fig. S6c) , and 42 transcripts were significant at p < 0.05 (Fig. S6d) . A total of 483 RNAs were differential expressed (≥2-fold) between CD63 + and MHC1 + EVs (Fig. S6e ), but differences in only 9 transcripts were significant p < 0.05 (Fig. S6f) . Therefore, EVs with CD47, CD63 and MHC1 surface markers have similar overall contents of non-coding RNAs, but each subset selectively enriches specific classes of non-coding RNAs.
Figure 5. RNAs enriched in CD63
+ EVs. Analysis of specific classes of RNAs in the 271 differentially expressed non-coding RNAs that were enriched ≥ 2-fold in CD63
+ EVs versus CD63 -EVs were extracted from the scatter graph in Fig. 3b + and CD63 + EVs, and the remaining 3 were enriched ≥ 2-fold in two of the three subsets. Six snoRNAs (SNHG17, SNHG20, SNORA50C, SNHG15, SNORA8, and SNORA40) were enriched in all three types of captured EVs, and most others were enriched in 2 of the 3 (Figs 4a, 5a and 6a). Long noncoding RNA enrichment showed more heterogeneity, with only LOC105379507, LOC107986280, and LOC283140 consistently enriched in EVs expressing each of the three markers (Figs 4c, 5c and 6c) . Among the tRNAs, only TNRV was ≥ 2-fold enriched in EVs expressing each of the three markers (Figs 4b, 5b and 6b) . + EVs. Analysis of specific classes of RNAs in the 268 differentially expressed non-coding RNAs that were enriched ≥ 2-fold in MHC1 + EVs versus MHC1 − EVs were extracted from the scatter graph in Fig. 3c 
CD63
+ and CD47 + EVs contain more miRNAs as compared to MHC1 + EVs. To align miRNAs in the RNAseq data, fastq files were assembled using SeqMan with NGen miRbase 2.1 as the reference. The percentages of aligned sequences are shown in the bar graph in Fig. S7a . A scatter plot of CD47 + vs CD47 − miRNA expression values (RPM) determined by RNA sequencing analysis using a statistical t-test identified a total of 186 miRNAs with p < 0.05 (all microRNA species included, Figs 7a and S7c). Among them 8 human miRNAs were enriched in CD47 + EVs (Fig. 7b) . Eleven human miRNAs are differentially regulated in CD47 + EVs versus CD63
+ EVs (Fig. 7c) , while 21 human miRNAs are found differentially expressed between CD47 + EVs and MHC1 + EVs (Fig. 7d) . The t-test for CD63 captured versus uncaptured EVs showed that a total of 208 miRNAs were differentially expressed at p < 0.05 (All species included, Figs 8a and S7c). Among them miR-3539-3p, miR-93-5p, miR-142, miR-150, miR-28-3p, miR-423-5p, let-7d and let-7i are highly enriched in CD63
+ EVs (Red font- Fig. 6b) . Some of the same enriched miRNAs were also identified in CD47 + and MHC1 + EVs (Blue font). Conversely, eleven human miRNAs are differentially enriched in CD63 + EVs versus MHC1 + EVs (Fig. 8c) , while only 3 miRNAs are differentially enriched between CD63 + EVs versus CD47 + EVs (Fig. 8d) . A scatter plot of miRNAs (all species) between MHC1 + versus MHC1 − EVs showed that 135 miRNAs are differentially regulated at p < 0.05 (Fig. S7d) . Among them miRNA-106b, miR-185-5p, miR-3610, miR-620 and miR-663 were enriched with MHC1 + EVs (Fig. S8a) (Fig. S8b) . However, interpretation of this comparison is limited by the low RPM for this RNA class in MHC1 + EVs. miRNA microarray analysis of CD63 + and CD47 + EVs captured using streptavidin magnetic beads. To independently confirm and extend the above RNAseq analysis of miRNAs, bulk Jurkat T cell-derived EVs were captured using biotinylated CD63 or CD47 antibodies coupled to streptavidin magnetic beads (Fig. 9a) . The CD63 and CD47 captured and uncaptured fractions of EVs were subjected to the same total RNA extraction as above and analyzed using miRNA microarrays. The miRNA microarray results show differentially expressed miRNAs in the captured versus uncaptured EVs (Fig. 9b,c) . The miRNAs highly enriched in the respective captured versus uncaptured EVs are shown in Fig. 9d ,e. The microarray data confirmed some of the RNAseq data, including the enrichment of miR-320 in CD47 + EVs. Further comparison of the miRNA microarray data for CD47 + and CD63 + EVs isolated by magnetic bead capture with RNA sequencing data for the corresponding EVs isolated by MNP capture confirmed significant enrichment of 21 miRNAs and significant depletion of 15 miRNAs. However, 24 other miRNAs showed divergent changes using the two methods (Fig. S8c) .
Validation of small non-coding RNA-Sequencing Analysis. Our noncoding RNAseq analysis using Method II indicated that MHC + EVs contain higher levels of some tRNAs than CD63 + EVs, including TRR-CCG (Fig. 10a) . To confirm this finding we performed tRNA real-time PCR analysis for CD63
+ and MHC1 + EVs and the corresponding depleted EV fractions (Fig. 10b and c) . As expected, CD63
− and MHC1 − EVs had similar levels of these tRNAs, whereas MHC1
+ EVs had higher levels of TRE-CTC and TRE-TRR compared to CD63 + EVs. qPCR was also used to validate selected differentially enriched small nucleolar RNAs identified using RNAseq. The former data indicated that SNHG5 is enriched in CD63 + , CD47 + , and MHC1 + EVs (Figs 4a, 5a, 6a and 10c). Analysis of SNHG5 using a TaqMan assay confirmed its enrichment in CD63 + , and MHC1 + EVs (Fig. 10d) . The RNAseq data indicated that SNHG10 and SNORD116@ are highly enriched only in CD47 + EVs (Fig. 10c) , and TaqMan real-time PCR data confirmed this finding (Fig. 10d) . CD47 + EVs had fewer snRNAs as compared to CD63 + EVs and MHC1 + EVs (Fig. 3f) , and we confirmed decreased expression of U6 Small Nuclear 1 using real time PCR analysis (Fig. 10e) . The snRNA profile of MHC1 + EVs showed high expression of RNU6ATAC (Fig. 6f) , and we have confirmed this using a TaqMan assay (Fig. 10e) . miRNA sequencing analysis (Method III) revealed high expression of miRNA-320a in CD47 + EVs. This was validated using magnetic bead captured CD47 + and CD63 + EVs (Fig. 9a ) with miRNA microarray analysis (Fig. 9b-e) . Both methods showed that CD47 + EVs are enriched with miRNA-320a (Figs 7b and 9d ). Microarray analysis also showed high expression of miRNA-320b. We further analyzed these microRNAs using real time PCR analysis and confirmed that miRNA-320a but not miRNA-320b is enriched in CD47 + EVs but not in CD63 + or MHC1 + EVs (Fig. 10g and h ).
Discussion
Our previous analysis of EVs released by Jurkat T cells that express CD47 with EVs released by a CD47-deficient Jurkat mutant identified differences in their content of coding mRNAs, but it was unclear whether CD47 played a direct or an indirect role in determining which mRNAs are packaged into EVs 22 . Here we show that the small noncoding RNA content of CD47 + EVs differs from that of CD47 − EVs released by the same cells. Analysis of + or MHC1 + EVs. The present data provides a comprehensive analysis of multiple classes of smaller noncoding RNAs. CD47, CD63 and MHC1 antibodies each capture a minority of EVs, and some EVs express more than one of these markers. However, CD47-, CD63-and MHC1-depleted fractions retain the majority of the total EV-associated (f) snRNA expression of RNU6ATAC using total RNA from captured and uncaptured CD47, CD63 and MHC1 EVs via TaqMan assay. (g,h) miRNA expression of mir-320a and mir-320b using total RNA from captured and uncaptured CD47, CD63 and MHC1 EVs determined using real-time PCR.
RNA content. Based on the high efficiency of recapture using MNPs with the same antibody, this is not an artifact of the capture method, but instead probably indicates that a substantial fraction of EVs released by Jurkat T cells lack sufficient copies of the three proteins to enable antibody capture. The substantial differences in the degree of enrichment for specific RNAs in CD47 + , CD63 + and MHC1 + EVs suggests heterogeneity in the targeting of different classes of RNAs and specific transcripts and that these three surface protein markers identify functionally distinct classes of EVs. We can only draw conclusions for the single cell type used, but such functional heterogeneity probably exists in EVs released by other cell types.
Our results show that CD47 + EVs do not significantly enrich any small nuclear RNAs. Previous studies have identified mechanisms that enable sequence-specific sorting of miRNAs into EVs, but the present results suggest that other classes of noncoding RNAs are also sorted into EVs, and different sorting mechanisms must exist to target different RNAs to EVs identified by expression of each of these three surface proteins.
Further, we have shown that purification by magnetic capture of EVs expressing CD63 and CD47 using antibody-modified MNPs or streptavidin-magnetic beads results in similar miRNA profiles despite differences related to chip content, sequence mapping algorithms and the mirBase dataset content. Data from the miRNA microarrays generally confirmed the differences identified using miRNAseq analysis, but the microarrays have higher sensitivity for detecting miRNA given the low total percentage of miRNAs in the preparations used for generating the sequencing libraries. CD63
+ EVs captured using MNPs were enriched in 15 unique miRNAs, and 10 unique miRNAs were enriched in CD47 and MHC1 captured EVs. Microarray analysis showed that the CD47 + EVs captured with beads yield more miRNA than CD63 + EVs. Many of the miRNAs identified are unique to EVs bearing one of the three surface markers examined and are enriched in these EVs relative to the respective uncaptured EV fractions. Further studies are required to determine the molecular mechanisms by which miRNAs are selectively targeted to CD47 + , CD63 + and MHC1 + EVs. It is unclear whether the surface proteins play a direct or indirect role in the loading of specific RNA contents into EVs. miRNA sorting into EVs can be regulated by chromosome location 23 , regulation of miRNA biosynthesis 24 , Ras activation 25 , AGO2 activity 26 , neural sphingomyelinase 2 activity 27 , and sequence-specific sorting that may be mediated by several RNA-binding proteins 13, 28, 29 . Sequence-specific sorting is an attractive mechanism to account for the marker-dependent differences reported here, but further study is needed to define candidate motifs unique to EVs expressing each surface marker and identify RNA binding proteins that may recognize these motifs.
Another important conclusion is that none of these three proteins is a universal marker for EVs. A major fraction of EVs and their noncoding RNA content were not captured by any of the three antibodies used in this study. The copy numbers of these surface proteins may be a limiting factor. A previous study determined that 141,000 copies/cell of a surface protein resulted in 30-70 copies/EV 30 . The reported density of CD47 on a typical cell is lower (~250 molecules/µm 2, 31 , which corresponds to ~25 copies/120 nm EV. The minimal copy number for immunocapture by MNPs or beads remains to be determined. Because CD47 also interacts laterally with other membrane proteins and undergoes clustering, it is also possible that CD47 may be excluded from a fraction of the EVs released by Jurkat T cells. Apart from their heterogeneity as surface markers, a more important question concerns the potential roles CD47, CD63, and MHC1 play in determining the functional heterogeneity of EVs.
miRNAs that are specifically enriched in CD47 + EVs could have translational implications. CD47 + EVs are enriched in miR-320a, which has been associated with cardiac ischemia/perfusion injury by targeting heat shock protein-20 32 . CD47 is a major regulator of cell and tissue responses to stress 33 , and CD47 null mice or wild type mice following CD47 blockade are protected from cardiac, hepatic, vascular, and renal ischemic injuries [34] [35] [36] [37] [38] . Regulation of EV miRNA composition is one potential mechanism by which therapeutic blockade of CD47 confers tissue protection in treated animals. Future studies will also explore whether disease-associated miRNAs are enriched in EVs that bear specific surface markers. If so, immunoaffinity purification could enable more sensitive less invasive diagnostic procedures utilizing diseased patient sera or other body fluids. The small nucleolar RNAs SNHG10 and SNORD116@, which are enriched selectively in CD47 + EVs, were identified as a prognostic marker in human lung adenocarcinomas 39 and a marker for progression of gastric cancer, respectively 40 . In this context, the elevated expression of CD47 in many cancers could result in enrichment of tumor-associated miRNAs and other noncoding RNAs in CD47 + EVs 33 . Therefore, immunoaffinity enrichment of CD47 + EVs from blood and other body fluids could increase the sensitivity for detecting cancer-associated noncoding RNAs in liquid biopsies.
Materials and Methods
Materials. The Jurkat T cell line (E6.1) was purchased from ATCC, and the CD47-deficient Jurkat mutant JinB8 were provided by Dr. Eric Brown, Genentech 41 . The cells were maintained using RPMI 1640 containing 10% FBS, glutamine, penicillin, and streptomycin (Gibco). The Jurkat and JinB8 T cells used for experiments were maintained less than 6 weeks in culture.
EVs Isolation and labeling. The cultured Jurkat and JinB8 T cells were washed with PBS followed by a second wash with HITES medium (DMEM/F12 supplemented with, bovine serum albumin, hydrocortisone, insulin, transferrin, and trace elements) 42 . EVs were isolated from Jurkat T cells and were cultured overnight using HITES medium. The conditioned media from Jurkat T cells were collected, and cell debris were removed using centrifugation at 300 g for 5 minutes and 2500 g for 10 minutes respectively. Centrifuged media were concentrated using Ultra-4 centrifugal filters to about 1 ml volume and further centrifuged at 10,000 g for 10 minutes. EVs were isolated using an Exo-Quick kit (SBI) by incubating overnight at 4 °C. Isolated EVs were labeled with Bodipy-FL according to the manufacturer's protocol (Millipore Sigma). Immunocapture of EVs. To characterize surface antigens on extracellular vesicles released by Jurkat cells, EVs were captured by CD63-MNPs, MHC I-MNPs or by CD47-MNPs as previously described 43 . Briefly, 15 nm magnetic nanoparticles (MNPs) (Ocean NanoTech, Springdale, AR) were activated and coupled with 1 mg of monoclonal antibodies anti-CD63 (Biolegend, San Diego, CA), anti-MHC (HLA-A,B,C Biolegend, San Diego, CA) or anti-CD47 clone B6H12 (eBiosciences) according to the manufacturer's protocol. After coupling, antibody(Ab)-MNP complexes were suspended in 2 ml of wash/storage buffer and stored at 4 °C. To capture and stain surface antigens of EVs, MNP-Ab complexes (~3.9 × 10 12 particles in 60 μl) were incubated with preparation of labeled EVs for 1 h at 4 °C, followed by addition of fluorescent monoclonal antibodies (anti-CD47-PE (Biolegend, San Diego CA for CD63-MNPs and MHC-MNPs capture or anti-CD63 PE (Biolegend, San Diego CA) for CD47-MNPs capture) and incubated for addition 20 minutes at room temperature. Controls were incubated with isotype control antibodies mouse IgG1k-PE (Biolegend, San Diego CA. Immunocaptured EVs stained for surface marker were separated from non-captured EVs and free floating antibodies on magnetic columns in a strong magnetic field generated by an OctoMacs magnet (Miltenyi Biotech), washed three times with 600 µl of washing buffer (0.5% bovine serum albumin, 2 mM EDTA in PBS). To elute captured EVs from columns, columns were removed from the magnet, flashed with 400 μl of PBS and fixed with 1.5% paraformaldehyde. The eluted complexes were analyzed on the LSRII cytometer triggering on fluorescence. Prior to analysis on the flow cytometer, a known number of 123-count eBeads (eBioscience, San Diego CA) counting beads were added to each sample. The volume of sample analyzed was estimated based on the number of 123 count eBeads acquired in each sample. Based on this volumetric measurement, the numbers of recorded events were normalized to calculate EV concentrations. NanoSight Analysis. EV concentration and size measurements were performed on a NanoSight NS 300 (Salisbury,United Kingdom) equipped with a 405 nm laser and analyzed with NTA 3.0 (NanoSight NS300, Malvern Instruments, UK). The measurements were performed with constant sample flow using a syringe pump for 180 sec at camera level 13.
Analysis of EVs
RNA extraction, cDNA library and RNA sequencing. Jurkat T cell-derived EVs were isolated using the Exo-Quick kit, and CD63 + , MHC1 + , and CD47 + EVs were captured using MNPs conjugated with the respective antibodies. Total RNA was extracted from the captured CD63 RNA assembly and small RNA Sequencing Work Flow Analysis. The fast Q Illumina files were imported using QSeq/ArrayStar software package (DNASTAR, Inc.) Total RNA sequencing analysis was performed using default settings of QSeq/ArrayStar software by comparing the individual sequence reads to a whole genome reference using Homo sapiens. GRCh38 (Fig. S5(I) . RNA sequencing reads were aligned by DNASTAR SeqMan NGen to either small coding/noncoding RNAs (CDS, rRNA, tRNA, ncRNA, tmRNA and miscRNA) or to miRNA reference (mature and precursors). We used miRNA sequencing DNASTAR ArrayStar work flow which databases. To yield long noncoding RNAs and other small RNAs (Fig. S5(II) . To evaluate miRNA, we used a SeqMan aligned assembly with miRbase, and analysis was performed using RNA-Seq analysis (Fig. S5(III) . The raw data is deposited in NCBI Gene Expression Omnibus (GEO): GSE103493.
RNA Sequencing Analysis. Whole human genome Human reference was downloaded using Domain menu (EUKAROTA) and from the organism menu, Homo sapiens was selected. The fast Q Illumina files were imported using QSeq/ArrayStar software package (DNASTAR, Inc.) Total RNA sequencing analysis was performed using default setting of QSeq/ArrayStar software by comparing the individual sequence reads to a whole genome reference. The mapped and unmapped reads were shown in a Table S3 . The normalization method RPKM used. Individual classes of noncoding RNAs were extracted from linear total RPKM Gene Table by name and a table was generated for each type of RNA. The cutoff threshold 0.02 log 2 total RPKM was used to filter RNAs from CD47 + , CD63 + and MHC1 + EVs, and the counts are shown in the pie charts (Fig. 2) . Similarly, the number and type of non-coding RNAs identified in CD47 Small RNA Sequencing Analysis. A whole human genome reference was downloaded using the Domain menu (EUKAROTA) selecting Homo sapiens from the organism menu. The fastq Illumina files were imported using the QSeq/ArrayStar software package (DNASTAR, Inc.). The mapped and unmapped reads were shown in a Table S4 . miRNA sequencing analysis was performed using QSeq Advanced Options Peak Detection setting, 'Simple Peak Finder' with minimum number of reads within the region set to 3 by comparing the individual sequence reads to a whole genome reference with features (CDS, rRNA, tRNA, ncRNA, tmRNA and miscRNA). The only normalization method available for this approach is RPM. Statistical analysis used Student's t-test to compare captured and uncaptured treatments.
miRNA-RNA Sequencing Analysis for miRNAs. An alternative analysis of miRNA expression used miRbase (hairpin.fa and mature.fa) as the reference in the RNA-Seq workflow of SeqMan NGen however, miRbase is still evolving 45 and may have provisional annotations. Analysis of changes in miRNA expression was determined with the QSeq/ArrayStar software package (DNASTAR, Inc.) using RPM normalization in separate analyses. Statistical significance was calculated using a Student's t-test to compare captured and uncaptured treatments.
MiRNA Microarray analysis using CD63
+b EVs and CD47 +b EVs streptavidin magnetic bead pull down Assay. Jurkat T cell derived EVs were extracted using Exo-Quick kit as described above. The precipitated EVs were pre-incubated with CD63 and CD47-Biotin (Biolegend) for 30 min using a rocker at 4 °C. Then 100 µl of streptavidin beads washed with IX PBS were added to the EVs for 1 h. The bound (CD63 and CD47 captured) and unbound EVs (CD63 and CD47 uncaptured) were separated using a magnetic field, and harvested captured EVs were gently washed one time with PBS (Fig S9a) . RNA was extracted from the captured CD63 + , and CD47 + EVs and from the respective uncaptured fractions of CD63 -, and CD47 − EVs in triplicate (n = 3) with the Qiagen miRNeazy Mini kit (Cat# 217004). The miRNA-microarray were performed as described previously 46 .The raw data of miRNA-microarray is deposited in NCBI Gene Expression Omnibus (GEO): GSE103310. 100 ng of total RNA was used for the rtStar ™ First-Strand cDNA Synthesis Kit, and real time PCR was performed using rtStar ™ pre-designed Human tRNA Primer Sets for TRE-CTC, TRR-CCG along with Spike RNA as an internal control according to the manufacturer's instructions. For miRNA expression analysis, 50 ng of RNA was used to perform SuperScript ™ III first-strand synthesis, and miRNA expression was analyzed using Quanta-bioscience-IDT primers for mature miR-302a/b along with a universal control primer.
Sno and SnRNA Real-Time PCR. 50 ng of RNA was used to perform SuperScript ™ III First-Strand Synthesis, and miRNA expression was analyzed using TaqMan assays for SNGH10, SNGH5, SNORD116a and RNU6ATAC according to the manufacturer's instructions. A small nuclear RNA U6 primer was used as described 47 .
Visualization and Statistical Analysis. The default setting of ArrayStar for Student t-test was used to determine significant transcripts. Direction of fold change from contrasts in multivariate analysis of variance (ANOVA) is used for comparison of miRNA microarray and miRNA sequencing for captured CD63 + and CD47 + EVs, and p < 0.05 is considered as significant. ArrayStar's Scatter Plot was used for visual comparison of gene signals between captured vs uncaptured EVs replicated datasets. FDR < 0.1 (Benjamini-Hochberg) was applied to method I (Fig. S5 ). For the remaining analyses, unadjusted p < 0.05 was used.
